30 December 2024
BEXIMCO PHARMACEUTICALS
LIMITED
Annual General Meeting
Statement
Beximco Pharmaceuticals Limited
("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI
No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of
generic pharmaceutical products and active pharmaceutical
ingredients, today announces that all resolutions put before
shareholders at the Company's Annual General Meeting ("AGM") held
virtually on 29 December 2024 were duly passed.
The resolutions passed at the AGM
included the approval of 40% cash dividend for the year ended on 30
June 2024. The cash dividend being 40% of the nominal value per
ordinary share of Taka 10 (Taka 4.0 per ordinary share/per global
depository receipt ("GDR") held in respect of GDR holders) will be
paid to holders of ordinary shares/GDRs (who were on the register
of shareholders'/GDR holders' as on the date of record, i.e. 25
November 2024) on or before 28 January 2025. The cash dividend will
be paid after deduction of taxes as per Bangladesh Tax
law.
Additionally, the Special Resolution
to change the name of the Company from "Beximco Pharmaceuticals
Limited" to "Beximco Pharmaceuticals PLC." as per the provision of
the Companies Act, 1994 (as amended in 2020) and to effect the
change of the name in the relevant Clauses of the Memorandum and
Articles of Association of the Company was passed. Further
announcements will be made in due course when the name change will
come into effect.
The Annual Report for 2023-24 is
available from the Company's website, which includes the audited
accounts and a review of operations for the year ended on 30 June 2024.
For
further information please visit www.beximcopharma.com or
enquire to:
|
Beximco Pharma
|
|
S M Rabbur Reza, Chief Operating
Officer
Tel: +880 2 58611001, Ext.
20111
Mohammad Ali Nawaz, Chief Financial
Officer
Tel: +880 2 58611001, Ext.
20030
Mohammad Asad Ullah, FCS
Executive Director & Company
Secretary
Tel: +880 2 41060531, Ext.
10140
|
|
SPARK Advisory Partners Limited (Nominated
Adviser)
Mark Brady / Andrew
Emmott
Tel: +44 (0)20 3368 3551 /
3555
|
|
SP
Angel Corporate Finance LLP (Broker)
Matthew Johnson
Tel: +44 (0) 20 3470 0470
|
|
FTI
Consulting
Simon Conway / Victoria Foster
Mitchell / Sam Purewal
Tel: +44 (0)20 3727 1000
|
Notes to Editors
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading
manufacturer and exporter of medicines based in Bangladesh. Since
its inception in 1976, the Company remains committed to health and
wellbeing of people across all the continents by providing access
to contemporary medicines. Company's broad portfolio of generics
encompasses diverse delivery systems such as tablets, capsules,
liquids, semi-solids, intravenous fluids, metered dose inhalers,
dry powder inhalers, sterile ophthalmic drops, insulins, prefilled
syringes, injectables, nebuliser solutions, oral soluble films etc.
The Company also undertakes contract manufacturing for
multinational and leading global generic pharmaceutical
companies.
Beximco Pharma′s state-of-the-art
manufacturing facilities are certified by global regulatory
authorities of USA, Europe, Australia, Canada, GCC and Latin
America, among others and it has a geographic footprint in more
than 50 countries. More than 6000 employees are driving the company
towards achieving its aspiration to be among the most admired
companies in the region.
